在免疫血小板缺血症治疗中使用异构巴格的现实世界经验:一项回顾性队列研究
Dan Wang1,2, Cheng Chang3, Zhongmin Zou4
1Department of Hematology, The Second Affiliated Hospital of Army Medical University (Third Military Medical University), Chongqing, 400037, China.
European journal of medical research
|July 4, 2025
概括
在现实环境中,Hetrombopag有效治疗免疫性血小板缺血症 (ITP). 每日5毫克的剂量和较高的骨髓巨核细胞计数预测ITP患者的结果更好.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 有限的临床数据存在于 hetrombopag,一种新型的血栓形成素受体激动剂 (TPO-RA),在治疗免疫血栓缩 (ITP).
- 现实世界的证据对于了解在ITP管理中对hetrombopag的有效性和安全性至关重要.
研究的目的:
- 研究 hetrombopag 在患有免疫性血小板缺血症 (ITP) 的患者中的真实有效性和安全性.
- 评估与异血栓药物治疗相关的治疗应答率和安全概况.
主要方法:
- 一项涉及50名ITP患者的回顾性研究,这些患者接受了血单疗法 (每天2.5毫克或5.0毫克).
- 主要终点:在4周,8周和12周,血小板数≥50×109/L的响应者比例.
- 二级终点:对血巴格的安全性概况的评估.
主要成果:
- 在第12周观察到71%的反应率,反应的中位时间为7天.
- 从第2周开始,每天5毫克的剂量显示出明显更好的疗效,而不是每天2.5毫克.
- 较高的骨髓巨核细胞计数与第4周的治疗疗效正相关.
结论:
- Hetrombopag在现实世界ITP治疗中显示出有效性和良好的安全性.
- 起始剂量为5mg/d的异构巴格和高的巨核细胞计数可能表明优异的治疗结果.
相关概念视频
Venous Thrombosis III: Interprofessional Care
26
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
26
Anticoagulant Drugs: Low-Molecular-Weight Heparins
919
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
919
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
258
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
258


